Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 3 studies. This list may not include all unresolved or historical entries.

  • RBD4059 injectionRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: INJECTION

    View study and source
  • RBD4059 injectionRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: INJECTION

    View study and source
  • RBD4059 injectionRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: INJECTION

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 1
1
25%
Phase 2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

not_yet_recruiting125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruitingphase_2

Vortosiran for VTE Prevention

NCT07850453
completedphase_1

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

NCT05653037
completedphase_2

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease

NCT06717074
recruitingphase_2

A randomised active-controlled study to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

SYF35b2ecc457374fcbb51c3595d7d1583b

Clinical Trials (4)

Showing 4 of 4 trials
NCT07850453Phase 2

Vortosiran for VTE Prevention

Not Yet Recruiting
NCT05653037Phase 1

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

Completed
NCT06717074Phase 2

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease

Completed
SYF35b2ecc457374fcbb51c3595d7d1583bPhase 2

A randomised active-controlled study to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
4